[{"_1":2,"_3":-5,"_4":-5},"loaderData",{"_5":6,"_7":8},"actionData","errors","root",{"_101":102},"en-item",{"_9":10,"_10":11},"kind","item",{"_12":13,"_14":15,"_16":17,"_18":19,"_20":21,"_22":23,"_24":25,"_26":27,"_28":29,"_30":31,"_32":31,"_33":34,"_35":36,"_37":38,"_39":40,"_41":42,"_43":44,"_45":46,"_47":-5,"_48":49,"_50":-5,"_51":-5,"_52":53,"_54":55,"_56":57,"_58":42,"_59":42,"_60":61,"_62":42,"_63":64},"id","sx6l9h4xj6g36m28ch9eqyz9z","revision",2,"title","Repligen完成收购BioLife，后者将退市","originalTitle","8-K - REPLIGEN CORP (0000730272) (Filer)","summary","Repligen Corporation于2026年10月6日完成对BioLife Solutions, Inc.的并购，BioLife将不再作为独立法律实体存在，并终止在纳斯达克的上市地位。并购通过合并协议完成，BioLife股东将获得Repligen股票和现金。BioLife将向SEC提交退市申请，并停止提交定期报告。","reason","Repligen完成对BioLife的并购，BioLife将退市并终止报告义务。","source",{"_12":92,"_93":94,"_9":95,"_96":42,"_97":98,"_99":100},"links",{"_89":90,"_77":91},"publishedAt","2026-10-06T13:14:18.000Z","discoveredAt","2026-10-06T13:22:07.988Z","timelineAt","category","ai-products","tags",[83,84,85,86,87,88],"stockSymbols",[82],"score",60,"selected",true,"channel","news","story",{"_72":73,"_16":74},"x","readingMode","full","author","language","body",{"_64":76,"_77":-5,"_78":79,"_80":81},"outline",[],"relatedStories",[75],"indexable","markdownAvailable","group",{"_65":66,"_45":67,"_68":15,"_69":70,"_71":70},"hasTranslation","bodyLanguage","zh","factId","fXsMUtN4gh4Y",{"_72":73,"_16":74},"reportCount","additionalSourceCount",0,"developmentCount","publicId","625474ea-861d-442f-80e8-db92b0f3c3dc","BioLife被Repligen收购并退市",{"_72":73,"_16":74},"

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): October 6, 2026

REPLIGEN CORPORATION

(Exact name of registrant as specified in its charter)

\n\n\n\n\n\n\n\n\n\n\n\n\n\n

\n	\n	\n	\n
Delaware		001-14656		04-2729386
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

\n\n\n\n\n\n\n\n\n\n

41 Seyon Street

Waltham, Massachusetts

02453

(Address of principal executive offices)

(Zip Code)

(781) 250-0111

Registrant’s Telephone Number, Including Area Code

Not applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

\n\n\n

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

\n\n\n

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

\n\n\n

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

\n\n\n

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

\n\n\n\n\n\n\n\n\n\n\n\n\n\n

\n	\n	\n	\n
Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.01 par value per share		RGEN		Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

EXPLANATORY NOTE

On October 6, 2026, Repligen Corporation, a Delaware corporation (“Repligen”), completed its previously announced acquisition of BioLife Solutions, Inc., a Delaware corporation (“BioLife”), pursuant to the Agreement and Plan of Merger, dated as of July 21, 2026 (the “Merger Agreement”), by and among Repligen, Bravo Merger Sub I, Inc., a Delaware corporation and wholly owned subsidiary of Repligen (“Merger Sub 1”), Bravo Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of Repligen (“Merger Sub 2”), and BioLife.

Pursuant to the Merger Agreement, on October 6, 2026, Merger Sub 1 merged with and into BioLife (the “First Merger”), with BioLife surviving the First Merger as a direct, wholly owned subsidiary of Repligen, and immediately following the First Merger, BioLife merged with and into Merger Sub 2 (the “Second Merger,” and, together with the First Merger, the “Mergers”), with Merger Sub 2 surviving the Second Merger as a direct, wholly owned subsidiary of Repligen.

《合并协议》及其中所述的交易，包括合并，此前已在 Repligen 的注册声明表格 S-4（注册编号 No. 333-298546）中进行过描述，该文件于 2026 年 9 月 4 日由证券交易委员会（“SEC”）宣布生效，并且在 2026 年 9 月 4 日编制并提交给 SEC 的 BioLife 最终委托书（经补充后，称为“委托书”）。

第 2.01 项：资产收购或处置的完成。

本表格 8-K 的“解释性说明”中所述信息已引用至本第 2.01 项。

在第一次合并（“第一次合并生效时间”）生效时，BioLife 每股面值 0.001 美元的普通股（“BioLife 普通股”）在第一次合并生效时间之前已发行并流通的股份（除（i）由 BioLife 持有的库藏股或由 Repligen、合并子公司 1 或合并子公司 2 持有的股份，以及（ii）根据特拉华州法律已适当行使并完成的评估权，且未被撤回的股份外）自动转换为获得（A）0.1442 股 Repligen 普通股（该 Repligen 普通股为有效发行、全额支付且不可追索的股份，“股票对价”）和（B）11.25 美元现金（不计利息）（“现金对价”，与股票对价合称为“合并对价”）。在合并中未发行 Repligen 普通股的零碎股份，BioLife 股东因零碎股份而获得现金对价，具体如合并协议中所述。

在第一次合并生效时间之前：

\n\n\n\n\n

•

BioLife 普通股的期权（“BioLife 期权”）在第一次合并生效时间之前已发行，无论是否已行权，均完全行权，并以向持有人支付等值于（i）该 BioLife 期权所涉及的 BioLife 普通股数量减去（ii）等值于其总行权价格的 BioLife 普通股数量（扣除任何适用税款后）的 BioLife 普通股进行交换；

\n\n\n\n\n

•

BioLife 在第一次合并生效时间之前已发行的仅基于时间的限制性股票单位（“BioLife RSU”）被加速行权，全部行权，并以向持有人支付等值于任何适用税款扣除或代扣的 BioLife 普通股数量的 BioLife 普通股进行结算和支付。

\n\n\n\n\n

•

在首次合并生效时间前，BioLife 的受限股票单位奖项（“BioLife PSUs”）中尚未归属的奖项被加速归属，全部完成归属，并以 BioLife 普通股的形式向持有人结算并支付（假设在首次合并生效时间前最近可行日期衡量的适用业绩目标的达成情况中，以目标值或实际值中较高者为准，并扣除任何等值于应扣减或代扣税款的 BioLife 普通股）；以及

\n\n\n\n\n

•

BioLife 的未归属受限股票奖项（“BioLife RSAs”）被加速归属，全部完成归属，并以 BioLife 普通股的形式向持有人发放（扣除任何等值于应扣减或代扣税款的 BioLife 普通股）；

根据上述规定，BioLife 期权、BioLife RSUs、BioLife PSUs 和 BioLife RSAs 下可发行的所有 BioLife 普通股在首次合并生效时间自动转换为获得合并对价的权利。

前述摘要并非完整描述，其全文应参考并购协议的完整文本，该文本作为本表8-K的附录2.1附后，并在此引用。

并购协议作为本8-K表的附录附上，旨在向投资者和证券持有人提供有关其条款的信息。它并非旨在提供有关Repligen或BioLife的任何其他事实信息，也不旨在修改或补充其向美国证券交易委员会提交的公开报告中的任何事实披露。并购协议包含Repligen和BioLife作出的陈述、保证和承诺，这些仅用于并购协议的目的，可能受Repligen和BioLife在协商并购协议条款时同意的重要资格和限制的约束。此外，其中一些陈述和保证可能在任何指定日期并不准确或完整，并可能受双方之间的某些披露以及与Repligen或BioLife向美国证券交易委员会提交的文件中通常适用的物质性标准不同的合同标准的约束。此外，陈述和保证是为在并购协议各方之间分配风险而作出的，不应被依赖为确立事实事项。

第7.01项：根据法规FD的披露。

由于合并，BioLife 已不再作为一个独立的法律实体存在，因此不再满足纳斯达克资本市场（“Nasdaq”）的上市要求。在合并完成之际，2026年10月5日，BioLife 通知纳斯达克，预计合并将在2026年10月6日交易开始前完成，并请求纳斯达克（i）在2026年10月5日东部时间晚上8:00左右的盘后交易时段结束后暂停 BioLife 普通股的交易，（ii）在 BioLife 于2026年10月6日确认合并完成的前提下，自2026年10月6日营业结束时暂停 BioLife 普通股的交易，并（iii）在 BioLife 于2026年10月6日确认合并完成的前提下，向美国证券交易委员会（SEC）提交一份根据《1934年证券交易法》（修订版）第12(b)条的“从上市和/或注册中移除的通知”表格25，以实现 BioLife 普通股从纳斯达克的退市，并根据《证券交易法》第12(b)条取消 BioLife 普通股的注册。因此，BioLife 普通股将不再在纳斯达克上市。2026年10月6日，BioLife 通知纳斯达克，合并已经完成。

2026年10月6日，Repligen 发布了一则新闻稿，宣布完成了本报告第2.01项中描述的交易。该新闻稿作为本报告第8-K表的附件99.1提供。

此外，BioLife 计划向美国证券交易委员会提交一份表格15的“注册终止证明和通知”，以请求根据《证券交易法》第12(g)条取消 BioLife 普通股的注册，并相应地尽快暂停 BioLife 在《证券交易法》第13条和第15(d)条下的报告义务，并停止向 BioLife 提交任何进一步的定期报告，因为 BioLife 已不再是一家上市公司。

本报告第8-K表中第7.01项的内容以及附带的附件99.1中的信息，不得视为根据《证券交易法》第18条“提交”的内容，也不受该条的任何责任约束，也不得视为在任何根据《1933年证券法》（修订版）或《证券交易法》提交的文件中通过引用纳入，除非在该文件中明确通过具体引用说明。

第9.01项：财务报表和附件。

(a) 被收购业务的财务报表。

如果需要，Repligen 计划在本报告第8-K表的修正案中提交财务报表，以符合第9.01(a)项的要求，最晚不迟于本报告第8-K表应提交日期后的71个日历天。

(b) 模拟财务信息。

如果需要，Repligen 计划在本报告第8-K表的修正案中提交模拟财务信息，以符合第9.01(b)项的要求，最晚不迟于本报告第8-K表应提交日期后的71个日历天。

(d) 附件。

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n

\n\n	\n
附件编号		描述
\n
2.1*		2026年7月21日签订的协议与合并计划，由BioLife Solutions, Inc.、Repligen Corporation、Bravo Merger Sub I, Inc.和Bravo Merger Sub II, LLC之间签订（引用自Repligen Corporation的2026年7月22日提交的8-K表格的第2.1项附录）。
\n
99.1		2026年10月6日的新闻稿（随本文件一同提供）。
\n
104		封面页面交互式数据文件（以inline XBRL文档格式）。

\n\n\n

*	本附录的部分内容根据法规S-K第601(a)(5)项的规定被省略。Repligen将在SEC要求时提供任何被省略的附录和附表；但Repligen可依据《交易法》第24b-2项的规定，就所提供的任何附录或附表请求保密处理。

签名

根据1934年《证券交易法》的要求，注册人已 duly 促使本报告由下文签署人 duly 授权代表签署。

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n

\n\n	\n	\n\n	\n	\n\n	\n
\n		\n		REPLIGEN CORPORATION
\n	\n	\n
日期：2026年10月6日		\n		由：		/s/ Olivier Loeillot
\n		\n		姓名：		Olivier Loeillot
\n		\n		职位：		首席执行官

","original","zhKind","translation","complete",false,"RGEN","公司与财报","并购","政策与监管","行业与主题","市场观察","其他","aihot","/items/sx6l9h4xj6g36m28ch9eqyz9z","https://www.sec.gov/Archives/edgar/data/730272/000119312526415015/0001193125-26-415015-index.htm","rss-sec-xbrl","name","SEC · EDGAR 财务披露","rss","firstParty","iconUrl","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar&exp=1791504000&sig=503fb7d170765eee","iconSrcSet","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-48&exp=1791504000&sig=bd7a734cec863d9b 48w, /api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-96&exp=1791504000&sig=e5a5cfd96e0c1fd2 96w","changelogVersion","2026-10-01T08:00"]